Atlas market file · Etf · United States
YieldMax MRNA Option Income Strategy ETFMRNY
- Last close
- 15.24
- Change
- +7.17%
- 96-bar range
- 14.01 – 22.15
- As of
- 7 Aug 2026
YieldMax MRNA Option Income Strategy ETF is an exchange-traded fund listed as MRNY on AMEX. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
MRNY
Etf · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-86.02% over the window).
Source rail: Yahoo Finance chart API (MRNY). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for MRNY. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
MRNY public profile
Exchange-traded fund. YieldMax MRNA Option Income Strategy ETF is connected to current market context, cited company sources and its retained research file.
YieldMax MRNA Option Income Strategy ETF trades as MRNY on AMEX. YieldMax MRNA Option Income Strategy ETF (MRNY) has a latest verified close of 15.24, up 7.17%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. MRNY stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.
What changed for YieldMax MRNA Option Income Strategy ETF today
The YieldMax MRNA Option Income Strategy ETF (MRNY) launched with a promise to blend biotech exposure and income generation, but its actual holdings tell a more conservative story. According to its SEC filing, the fund allocates 45% to cash and money market instruments, with the remainder split among Moderna, BioNTech, and Pfizer-companies more associated with legacy pharmaceuticals than mRNA disruption.
MRNY charges an expense ratio of 0.95%, which FINRA data shows is significantly higher than the average 0.35% for equity income ETFs. This fee structure raises questions about the value proposition when over half the portfolio sits in low-yielding cash equivalents. Liquidity also remains a concern: Nasdaq data reveals average daily trading volume of just 12,000 shares, suggesting limited appeal for active traders.
The fund’s marketing emphasizes "option income strategy," but filings disclose a collar strategy that limits both upside and downside-broadly a range-bound bet on mega-cap pharma stocks. While the mRNA theme attracts attention, the reality is a moderately concentrated portfolio with elevated fees relative to its peers. No recent news or filings address plans to adjust this structure.
What remains unproven is whether MRNY can attract sufficient assets to justify its premium pricing or whether its cash-heavy stance will evolve as the mRNA sector matures. Investors seeking pure biotech exposure may find more direct options, while those prioritizing income should weigh the fee drag against the fund’s modest yield potential.
Sources & evidence · 3 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
MRNY technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on MRNY
FreedomCore Atlas can expand this public profile into source-led research files with holdings and concentration, index methodology, exposure and overlap, fees and tracking difference, and liquidity context. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep MRNY research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
MRNY FAQ
What is YieldMax MRNA Option Income Strategy ETF (MRNY)?YieldMax MRNA Option Income Strategy ETF (MRNY) has a latest verified close of 15.24, up 7.17%, dated 7 Aug 2026. Use this page to check the price chart, company...
YieldMax MRNA Option Income Strategy ETF (MRNY) has a latest verified close of 15.24, up 7.17%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for MRNY?YieldMax MRNA Option Income Strategy ETF (MRNY) has a latest verified close of 15.24, up 7.17%, dated 7 Aug 2026. It brings the latest available chart, company context,...
YieldMax MRNA Option Income Strategy ETF (MRNY) has a latest verified close of 15.24, up 7.17%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. MRNY stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.
How often is the MRNY page updated?The MRNY public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The MRNY public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for MRNY?The MRNY file starts with Nasdaq Trader and TradingView AMEX:MRNY. The page separates verified market context from company evidence and shows open evidence gaps instead...
The MRNY file starts with Nasdaq Trader and TradingView AMEX:MRNY. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on MRNY?Yes. The workstation can open MRNY, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open MRNY, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this MRNY page investment advice?No. The MRNY page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The MRNY page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →